Extended Data Fig. 5: Dose-dependent mRNA-1273-elicited antibody responses reveal strong positive correlation between binding and pseudovirus neutralization titres.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
a–c, BALB/c mice (n = 10/group) were immunized at weeks 0 and 3 weeks with various doses (0.0025–20 μg) of mRNA-1273. Sera were collected 2 weeks post-boost and assessed for SARS-CoV-2 S-specific IgG by ELISA (a) and neutralizing antibodies against homotypic SARS-CoV-2 pseudovirus (b). a, b, All doses were compared to the 20 μg dose by two-sided Mann–Whitney U-test in a stepwise fashion, such that lowest doses were tested first at α = 0.05 and higher doses tested only if the lower doses were significant. Data are presented as GMT ± geometric s.d., and dotted lines represent assay limits of detection. c, Spearman correlation test was used to correlate binding antibody titres to pseudovirus neutralizing antibody titres (P < 0.0001). Each dot represents an individual mouse. Dotted lines highlight log10 IC50 boundaries. **P < 0.01, ***P < 0.001.
